DUBLIN--(BUSINESS WIRE)--The "Global Molecular Diagnostics 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.
The Global Molecular Diagnostics Partnering 2010-2018 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.
The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
One of the key highlights of the report is that over 660 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Molecular Diagnostics dealmaking
Chapter 3 - Leading Molecular Diagnostics deals
Chapter 4 - Most active Molecular Diagnostics dealmakers
Chapter 5 - Molecular Diagnostics contracts dealmaking directory
Chapter 6 - Molecular Diagnostics dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/zxz27c/global_molecular?w=4
